This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus
by Zacks Equity Research
Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.
Medtronic Gets FDA Nod for Guardian CGM's Android Version
by Zacks Equity Research
Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.
Company News for May 22, 2020
by Zacks Equity Research
Companies In The News Are: MDT, BJ, SNPS, EXPE.
Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks.com
Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.
Medtronic (MDT) Misses Q4 Earnings Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of -1.69% and 1.20%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty
by Zacks Equity Research
Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $96.76, marking a -1.16% move from the previous day.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $100.72, marking a +1.43% move from the previous day.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $95.73, moving -1.63% from the previous trading session.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $101.04, marking a +1.77% move from the previous day.
PETQ vs. MDT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PETQ vs. MDT: Which Stock Is the Better Value Option?
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns
by Zacks Equity Research
Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.
The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $86.26, marking a +0.13% move from the previous day.
Top Research Reports for Amazon, Medtronic & Vertex
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX).
3 Must-Buy Stocks as Coronavirus Cases Spike (Revised)
by Zacks Equity Research
COVID-19 has increased the demand for ventilators and personal protective equipment, which can aid these three companies at large.
The Zacks Analyst Blog Highlights: General Motors, Tesla, Cardinal Health, ResMed and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Motors, Tesla, Cardinal Health, ResMed and Medtronic
STERIS' (STE) Organic Growth Robust Amid Bottom-Line Hurdles
by Zacks Equity Research
STERIS (STE) continues to register stellar organic growth across all four operating segments.
Medtronic's Evolut TAVR System Shows Positive Study Results
by Zacks Equity Research
Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.
Syneos Health Launches Initiative for COVID-19 Patients
by Zacks Equity Research
The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.